Duell, J., Abrisqueta, P., Andre, M., Gaidano, G., González Barca, E., Jurczak, W., . . . Salles, G. (2023). Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: Final 5-year efficacy and safety findings in the phase II L-MIND study.
Citação norma ChicagoDuell, Johannes, et al. Tafasitamab for Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma: Final 5-year Efficacy and Safety Findings in the Phase II L-MIND Study. 2023.
Citação norma MLADuell, Johannes, et al. Tafasitamab for Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma: Final 5-year Efficacy and Safety Findings in the Phase II L-MIND Study. 2023.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.